129 related articles for article (PubMed ID: 19052491)
1. [The effect of levothyroxine suppression therapy for benign thyroid nodules on bone metabolism in premenopausal women].
Akinci B; Demir T; Cömlekçi A; Karaoğlu O; Seçil M; Yeşil S
Kulak Burun Bogaz Ihtis Derg; 2008; 18(4):232-7. PubMed ID: 19052491
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
3. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
4. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
5. Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal.
Gao YC; Gu Q; Liu QP; Ge WL; Lu HK
Clin Lab; 2010; 56(3-4):87-93. PubMed ID: 20476639
[TBL] [Abstract][Full Text] [Related]
6. Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation.
Demir T; Akinci B; Comlekci A; Karaoglu O; Ozcan MA; Yener S; Yuksel F; Secil M; Yesil S
Clin Endocrinol (Oxf); 2009 Sep; 71(3):446-50. PubMed ID: 19138314
[TBL] [Abstract][Full Text] [Related]
7. [The effects of levothyroxine replacement therapy on bone and mineral metabolism in patients with hypothyroidism].
Chai R; Ye Z; Zhan Z; Liu W; Yu M; Liu Y
Zhonghua Nei Ke Za Zhi; 1999 Jan; 38(1):18-21. PubMed ID: 11798620
[TBL] [Abstract][Full Text] [Related]
8. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women.
Uretmen S; Gol M; Cimrin D; Irmak E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):67-71. PubMed ID: 16051419
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
11. Dietary calcium, sodium, phosphorus, and protein and bone metabolism in elderly Japanese women: a pilot study using the duplicate portion sampling method.
Nakamura K; Hori Y; Nashimoto M; Okuda Y; Miyazaki H; Kasai Y; Yamamoto M
Nutrition; 2004 Apr; 20(4):340-5. PubMed ID: 15043848
[TBL] [Abstract][Full Text] [Related]
12. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
Khmara IM; Tolkachev IuV
Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
[TBL] [Abstract][Full Text] [Related]
13. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
[TBL] [Abstract][Full Text] [Related]
14. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
15. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
Akinci B; Demir T; Comlekci A; Yener S; Ozcan MA; Karaoglu O; Yuksel F; Secil M; Yesil S
Med Princ Pract; 2011; 20(1):23-8. PubMed ID: 21160209
[TBL] [Abstract][Full Text] [Related]
16. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal study of bone-related biochemical changes at the menopause.
Nordin BE; WIshart JM; Clifton PM; McArthur R; Scopacasa F; Need AG; Morris HA; O'Loughlin PD; Horowitz M
Clin Endocrinol (Oxf); 2004 Jul; 61(1):123-30. PubMed ID: 15212654
[TBL] [Abstract][Full Text] [Related]
18. Effect of calcium fortified milk supplementation with or without vitamin K on biochemical markers of bone turnover in premenopausal women.
Kruger MC; Booth CL; Coad J; Schollum LM; Kuhn-Sherlock B; Shearer MJ
Nutrition; 2006; 22(11-12):1120-8. PubMed ID: 17030114
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
20. Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study.
Woitge HW; Knothe A; Witte K; Schmidt-Gayk H; Ziegler R; Lemmer B; Seibel MJ
J Bone Miner Res; 2000 Dec; 15(12):2443-50. PubMed ID: 11127208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
